

*MedTech Agenda*

*Attendees are Provisional*

**Classical and Novel Biomarkers and Omics in CVD –  
Driving Toward More Medical Value**

*Enhancing CV Therapeutic Benefit by  
Precision Medicine*

**Eighteenth Annual Meeting: Transatlantic Heart Failure  
Biomarker Working Group**

**Cannes, France**

**April 22nd – 23rd, 2023**

**Scientific Programme**

***Chairmen:***

***Kirkwood F. Adams, Jr. (Chapel Hill, US)***

***Faiez Zannad (Nancy, FR)***

# Meeting Agenda

*Cannes Hotel Le Gray d'Albion*

## Session 1

### Latest Applications of Biomarkers in CVD

**Saturday Morning April 22, 2023**

**8:00 - 8:05 AM Overview** *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*  
*Faiez Zannad, MD, PhD (Nancy, FR)*

#### **Novel Application of Biomarkers to Optimize Clinical Care in Cardiovascular Disease**

**Moderator** *Alexandre Mebazaa, MD (Paris, FR)*

**8:05 - 8:45 AM** Investigator Viewpoint *Leong Ng, MD (Leicester, UK)*  
Investigator Viewpoint *James Januzzi, Jr., MD (Boston, US)*  
Investigator Viewpoint *Antoni Bayes-Genis, MD, PhD (Barcelona, ES)*  
Investigator Viewpoint *Yigal Pinto, MD, PhD (Amsterdam, NL)*  
Investigator Viewpoint *Christopher deFilippi, MD (Baltimore, US)*  
Industry Viewpoint *Gillian Murtagh, MD, MBA (Abbott)*

**8:45 - 9:30 AM Group Discussion**

#### **Latest on Sepsis Biomarkers and Biotargets – Progress in Precision Medicine**

**Moderator** *Kirkwood F. Adams, Jr, MD (Chapel Hill, US)*

**9:30 - 10:05 AM** Investigator Viewpoint *Alexandre Mebazaa, MD (Paris, FR)*  
Industry Viewpoint *Karine Bourgeois, PhD (4TEEN4)*  
Industry Viewpoint *Joachim Struck, PhD (Adrenomed)*

**10:05 - 10:40 AM Group Discussion**

**10:40 - 10:55 AM Break**

#### **Progress in Biomarkers and Omics Markers To Predict Heart Failure**

**Moderator** *John Cleland, MD (Glasgow, UK)*

**10:55 - 11:35 AM** Investigator Viewpoint *Faiez Zannad, MD, PhD (Nancy, FR)*  
Investigator Viewpoint *Job A.J. Verdonschot, MD, MSc (Maastricht, NL)*  
Investigator Viewpoint *Tom Lumbers, MD (London, UK)*  
Investigator Viewpoint *Javed Butler, MD, MPH (Dallas, US)*  
Investigator Viewpoint *Anders Målarstig, PhD (Stockholm, SE)*

**11:35 AM - 12:15PM Group Discussion**

**12:15 - 1:15 PM Lunch**

# Meeting Agenda

*Cannes Hotel Le Gray d'Albion*

## Session 2

### Translation of Biomarker Science to Clinical Science

Saturday Afternoon April 22, 2023

#### HFpEF: Redefining this Syndrome - Role of Biomarkers in Understanding Phenotypes and Therapeutic Responses

**Moderator** *Arantxa González, PhD (Pamplona, ES)*

**1:15 - 1:50 PM** Investigator Viewpoint *Robert Mentz, MD (Durham, US)*  
Investigator Viewpoint *Arantxa González, PhD (Pamplona, ES)*  
Investigator Viewpoint *Javed Butler, MD, MPH (Dallas, US)*  
Investigator Viewpoint *Jasper Tromp, MD (Singapore, SG)*  
Investigator Viewpoint *Javier Diez, MD, PhD (Pamplona, ES)*

**1:50 - 2:30 PM** **Group Discussion**

#### Novel Pathophysiological Insights in Heart Failure: Role of Omics and Biomarkers

**Moderator** *David Lanfear, MD, MS (Detroit, US)*

**2:30 - 3:15 PM** Investigator Viewpoint *Thomas Thum, MD, PhD (Hanover, DE)*  
Investigator Viewpoint *João Ferreira MD, PhD (Nancy, FR)*  
Investigator Viewpoint *Natalia Lopez, PhD (Pamplona, ES)*  
Investigator Viewpoint *G. Michael Felker, MD, MHS (Durham, US)*  
Investigator Viewpoint *Pierpaolo Pellicori (Glasgow, UK)*

**3:15 - 3:55 PM** **Group Discussion**

**3:55 - 4:05 PM** **Break**

#### How Biomarkers May Help Understand Mechanisms of Action of HF Drugs

**Moderator** *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*

**4:05 - 4:45 PM** Investigator Viewpoint *Faiez Zannad, MD, PhD (Nancy, FR)*  
Investigator Viewpoint *Justin Ezekowitz, MB, BCh (Edmonton, CA)*  
Industry Viewpoint *Mikhail Sumin, PhD (Boehringer-Ingelheim)*  
Industry Viewpoint *Karsten Strauss, PhD (Olink)*

**4:45 – 5:30 PM** **Group Discussion**

**5:30 PM** **Adjourn for the day**

# Meeting Agenda

*Cannes Hotel Le Gray d'Albion*

## Session 3

### CV Biomarkers in Clinical HF and CV Care Sunday Morning April 23, 2023

#### Cardio-Renal Disease – Markers of Pathophysiology and Congestion

**Moderator** *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*

**8:00 - 8:50 AM**      Investigator Viewpoint      *Jozine ter Maaten, MD, PhD (Groningen, NL)*  
Investigator Viewpoint      *Patrick Rossignol, MD, PhD, (Monaco, PT)*  
Industry Viewpoint      *Oliver Hartmann, PhD (SphingoTec)*  
Industry Viewpoint      *Sharin Roth, PhD (Otsuka)*  
Industry Viewpoint      *Serge Masson, PhD (Roche Dx)*

**8:50 - 9:30 PM**      **Group Discussion**

#### Clinical and Molecular Phenotyping to Enhance Precision Medicine in Heart Failure

**Moderator** *Robert Mentz, MD (Durham, US)*

**9:30 - 10:10 AM**      Investigator Viewpoint      *João Ferreira MD, PhD (Porto, )*  
Investigator Viewpoint      *Martin Hülsmann, MD (Vienna, AT)*  
Industry Viewpoint      *André Ziegler, PhD (Roche Dx)*

**10:10 - 10:40 AM**      **Group Discussion**

**10:40 - 10:55 AM**      **Break**

#### Reducing Treatment Gaps in HFrEF Rx - Role of Biomarkers and Other Novel Strategies - Pivotal Studies Going Forward?

**Moderator** *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*

**10:55 - 11:35 AM**      Investigator Viewpoint      *Alexandre Mebazaa, MD (Paris, FR)*  
Investigator Viewpoint      *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*  
Investigator Viewpoint      *Ileana Piña, MD, MPH (Philadelphia, US)*  
Investigator Viewpoint      *Stephanie Dunlap, (Augusta, US)*  
Investigator Viewpoint      *Sandra Sanders van Wijk, MD, PhD (Zuyderland, NL)*  
Investigator Viewpoint      *Hans-Peter Brunner-La Rocca MD (Maastricht, NL)*

**11:35 - 12:15 PM**      **Group Discussion**

**12:15 - 1:15 PM**      **Lunch**

# Meeting Agenda

*Cannes Hotel Le Gray d'Albion*

## Session 4

### Biomarkers for Precision Medicine

Sunday Afternoon April 23, 2023

#### Systems Biology, Bio-informatics and Complex Networks in HF Research

**Moderator** *Alexandre Mebazaa, MD (Paris, FR)*

**1:15 - 1:45 PM** Investigator Viewpoint *David Lanfear, MD, MS (Detroit, US)*  
Investigator Viewpoint *Wouter Ouwerkerk, PhD (Amsterdam, NL)*  
Investigator Viewpoint *Christian Bar, PhD (Hanover, DE)*

**1:45 - 2:30 PM** **Group Discussion**

#### Role of Biomarkers to Complement Bioimaging and Device Monitoring

**Moderator** *Roberto Latini, MD (Milan, IT)*

**2:30 - 3:00 PM** Investigator Viewpoint *Pierpaolo Pellicori (Glasgow, UK)*  
Investigator Viewpoint *John Cleland, MD (Glasgow, UK)*  
Investigator Viewpoint *Martin Hülsmann, MD (Vienna, AT)*  
Investigator Viewpoint *Nicolas Girerd, MD, PhD (Nancy, FR)*

**3:00 - 3:30 PM** **Group Discussion**

**3:50 - 4:05 PM** **Break**

#### Role of Biomarkers in Worsening HFrEF: Patient Profiling and Guide To Drug Treatment

**Moderator** *David Lanfear, MD, MS (Detroit, US)*

**4:05 - 4:50 PM** Investigator Viewpoint *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*  
Investigator Viewpoint *John Cleland, MD (Glasgow, UK)*  
Investigator Viewpoint *David Lanfear, MD, MS (Detroit, US)*  
Investigator Viewpoint *Adriaan Voors, MD (Groningen, NL)*

**4:50 - 5:30 PM** **Group Discussion**

**5:30 PM** **Meeting Wrap-up and Adjourn**